Insights

Gathering insights about Tolero Pharmaceuticals, Inc.…

Similar companies to Tolero Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc. Tech Stack

Tolero Pharmaceuticals, Inc. uses 8 technology products and services including Adobe, SAS, CIM Technologies, and more. Explore Tolero Pharmaceuticals, Inc.'s tech stack below.

Adobe
Audio, Video, Graphics
SAS
Business Intelligence
CIM Technologies
Cad & Graphics
Veeva Vault
Enterprise Content Management
jQuery
Javascript Libraries
Google Maps
Maps
Microsoft
Miscellaneous
Adobe Creative Suite
Visualisation Software

Media & News

Toleropharma partners with AbbVie Inc.
Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for hematologic and oncologic diseases, has entered into a clinical research collaboration with AbbVie, a research-based global biopharmaceutical company, exploring the potential of combination therapy with AbbVie's venetoclax and Tolero's investigational agent, alvocidib, for the treatment of relapsed/refractory acute myeloid leukemia (AML).
Aug 17, 2018 | www.prnewswire.com

Tolero Pharmaceuticals, Inc.'s Email Address Formats

Tolero Pharmaceuticals, Inc. uses at least 1 format(s):

Tolero Pharmaceuticals, Inc. Email Formats	Example	Percentage
FLast@toleropharma.com	JDoe@toleropharma.com	44%
Last@toleropharma.com	Doe@toleropharma.com	6%
FLast@toleropharma.com	JDoe@toleropharma.com	44%
Last@toleropharma.com	Doe@toleropharma.com	6%

Frequently Asked Questions

What is Tolero Pharmaceuticals, Inc.'s phone number?

You can contact Tolero Pharmaceuticals, Inc.'s main corporate office by phone at

+1-801-285-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Tolero Pharmaceuticals, Inc.'s official website and social media links?

Tolero Pharmaceuticals, Inc.'s official website is toleropharma.com and has social profiles on LinkedIn Crunchbase.

How much revenue does Tolero Pharmaceuticals, Inc. generate?

As of December 2025, Tolero Pharmaceuticals, Inc.'s annual revenue is estimated to be $1.9M.

What is Tolero Pharmaceuticals, Inc.'s SIC code NAICS code?

Tolero Pharmaceuticals, Inc.'s SIC code is 2834 - Pharmaceutical Preparations NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Tolero Pharmaceuticals, Inc. have currently?

As of December 2025, Tolero Pharmaceuticals, Inc. has approximately 11 employees across 2 continents, including North AmericaEurope. Key team members include Chief Medical Officer: S. W.Vice President Product Development: K. O. N.Co-Founder And Vice President Of Drug Discovery And Development: S. W.. Explore Tolero Pharmaceuticals, Inc.'s employee directory with LeadIQ.

What industry does Tolero Pharmaceuticals, Inc. belong to?

Tolero Pharmaceuticals, Inc. operates in the Pharmaceutical Manufacturing industry.

What technology does Tolero Pharmaceuticals, Inc. use?

Tolero Pharmaceuticals, Inc.'s tech stack includes AdobeSASCIM TechnologiesVeeva VaultjQueryGoogle MapsMicrosoftAdobe Creative Suite.

What is Tolero Pharmaceuticals, Inc.'s email format?

Tolero Pharmaceuticals, Inc.'s email format typically follows the pattern of FLast@toleropharma.com. Find more Tolero Pharmaceuticals, Inc. email formats with LeadIQ.

When was Tolero Pharmaceuticals, Inc. founded?

Tolero Pharmaceuticals, Inc. was founded in 2011.

Tolero Pharmaceuticals, Inc.

Q: How many employees does Tolero Pharmaceuticals, Inc. have currently?

Tolero Pharmaceuticals, Inc. has approximately 11 employees.

Q: What technology does Tolero Pharmaceuticals, Inc. use?

Tolero Pharmaceuticals, Inc.'s tech stack includes Microsoft, SAS/GRAPH, Microsoft Word, Segment, Oracle.

Pharmaceutical ManufacturingUtah, United States11-50 Employees

Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with serious oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.